1xbet모바일 Pharmaceutical Co., Ltd.
June 18, 2021
Approval in Japan for 1xbet모바일's minor BCR-ABL mRNA measurement kit
A marker to monitor treatment effectiveness 1xbet모바일 acute lymphoblastic leukemia (ALL)
1xbet모바일 Pharmaceutical Co., Ltd. announces today that it has received the first regulatory approval in Japan for the manufacture and sales of the 1xbet모바일 minor BCR-ABL mRNA measurement kit as an in-vitro diagnostic product.
The kit is for use diagnostic support and monitor treatment effectiveness for Philadelphia Chromosome- positive acute lymphoblastic leukemia (Ph+ALL) and 1xbet모바일 expects that the kit can support identification of the most appropriate treatment opportunities for patients in Japan with ALL.
1xbet모바일 patients with ALL, lymphocytes (a type of white blood cell) become malignant at an early stage of differentiation and proliferate unrestra1xbet모바일edly without matur1xbet모바일g 1xbet모바일to functional lymphocytes. Early diagnosis and treatment 1xbet모바일itiation are important because the condition progresses rapidly The number of patients 1xbet모바일 Japan was reported to be about 5,000 1xbet모바일 a survey by the Japanese MHLW 1xbet모바일 2017.
The Diagnostic Division of 1xbet모바일 has launched WT1 mRNA Measurement Kit II "1xbet모바일" and Major BCR-ABL mRNA Measurement Kit "1xbet모바일" as in-vitro diagnostic agents for blood cancer. 1xbet모바일 will continue to contribute to medical treatment with the aim of developing diagnostic agents that can maximize the capabilities of therapeutic agents.